Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

Business Wire

10 Feb

Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit)

Richard Malamut, Chief Medical Officer at Medincell comments: "Our partner is advancing the clinical development of the olanzapine LAI with plans for regulatory submission in the US. This structured approach highlights a strong commitment to addressing a critical unmet need. As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used by patients with schizophrenia."

MONTPELLIER, France, February 10, 2025--(BUSINESS WIRE)--Medincell (Paris:MEDCL):

ACCESS HERE THE FULL PRESS RELEASE

View source version on businesswire.com: https://www.businesswire.com/news/home/20250209967526/en/

Contacts

David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com / +33 (0)6 83 25 21 86

Grace Kim
Head of US Financial Strategy & IR
grace.kim@Medincell.com / +1 (646) 991-4023

Nicolas Mérigeau/ Arthur Rouillé
Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Louis-Victor Delouvrier/Alban Dufumier
Investor Relations France
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2510892848"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510892848\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2510892848?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-10 15:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2510892848","market":"us","top_or_hot":-1,"title":"Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals","media":"Business Wire","content":"<html><body>\n<figure>\n<img border=\"0\" height=\"295\" src=\"https://s1.yimg.com/uu/api/res/1.2/xepsNRg28VytrC4pFHrw2Q--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/3f65ce341d187adc8d3d67617cfcba28\" title=\"\" width=\"1772\"/>\n<figcaption></figcaption>\n</figure>\n<ul>\n<li><b><a href=\"https://laohu8.com/S/MDCLF\">Medincell</a> to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit)</b></li>\n</ul>\n<ul>\n<li><b>Richard Malamut, Chief Medical Officer at Medincell comments:</b> <i>\"Our partner is advancing the clinical development of the olanzapine LAI with plans for regulatory submission in the US. This structured approach highlights a strong commitment to addressing a critical unmet need. As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used by patients with schizophrenia.\"</i></li>\n</ul>\n<p><b>MONTPELLIER, France, February 10, 2025</b>--(BUSINESS WIRE)--Medincell (Paris:MEDCL):</p>\n<p>ACCESS HERE THE FULL PRESS RELEASE</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20250209967526/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>David Heuzé </b><br/>Head of Corporate and Financial Communications, and ESG<br/>david.heuze@Medincell.com / +33 (0)6 83 25 21 86<br/><br/></p>\n<p><b>Grace Kim </b><br/>Head of US Financial <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> & IR<br/>grace.kim@Medincell.com / +1 (646) 991-4023<br/><br/></p>\n<p><b>Nicolas Mérigeau/ Arthur Rouillé </b><br/>Media Relations<br/>Medincell@newcap.eu / +33 (0)1 44 71 94 94<br/><br/></p>\n<p><b>Louis-Victor Delouvrier/Alban Dufumier </b><br/>Investor Relations France<br/>Medincell@newcap.eu / +33 (0)1 44 71 94 94<br/><br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompletion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals\n</h2>\n<h4 class=\"meta\">\n\n\n2025-02-10 15:00 GMT+8   <a href=\"https://finance.yahoo.com/news/completion-pivotal-phase-3-trial-070000811.html\"><strong>Business Wire</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit)\n\n\nRichard Malamut, Chief Medical Officer at Medincell comments: \"Our ...</p>\n<a href=\"https://finance.yahoo.com/news/completion-pivotal-phase-3-trial-070000811.html\">Source Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4557","symbol_name":"大麻股","start_time":0,"source_url":"https://finance.yahoo.com/news/completion-pivotal-phase-3-trial-070000811.html","article_id":"2510892848","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510892848","pubTimestamp":1739170800,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion . Richard Malamut, Chief Medical Officer at Medincell comments: \"Our partner is advancing the clinical development of the olanzapine LAI with plans for regulatory submission in the US. This structured approach highlights a strong commitment to addressing a critical unmet need. As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used by patients with schizophrenia.\". David Heuzé Head of Corporate and Financial Communications, and ESGdavid.heuze@Medincell.com / +33 6 83 25 21 86. Grace Kim Head of US Financial Strategy & IRgrace.kim@Medincell.com / +1  991-4023. Louis-Victor Delouvrier/Alban Dufumier Investor Relations FranceMedincell@newcap.eu / +33 1 44 71 94 94","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4557":"大麻股","MDCLF":"Medincell","BK4559":"巴菲特持仓","BK4585":"ETF&股票定投概念","BK4596":"哈里斯概念","BK4588":"碎股","BK4566":"资本集团","BK4007":"制药","TEVA":"梯瓦制药","BK4584":"避孕概念"},"translate_title":"Teva Pharmaceuticals完成奥氮平LAI治疗精神分裂症的关键3期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1,"MDCLF":0.9},"content_text":"Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit)\n\n\nRichard Malamut, Chief Medical Officer at Medincell comments: \"Our partner is advancing the clinical development of the olanzapine LAI with plans for regulatory submission in the US. This structured approach highlights a strong commitment to addressing a critical unmet need. As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used by patients with schizophrenia.\"\n\nMONTPELLIER, France, February 10, 2025--(BUSINESS WIRE)--Medincell (Paris:MEDCL):\nACCESS HERE THE FULL PRESS RELEASE\nView source version on businesswire.com: https://www.businesswire.com/news/home/20250209967526/en/\nContacts\nDavid Heuzé Head of Corporate and Financial Communications, and ESGdavid.heuze@Medincell.com / +33 (0)6 83 25 21 86\nGrace Kim Head of US Financial Strategy & IRgrace.kim@Medincell.com / +1 (646) 991-4023\nNicolas Mérigeau/ Arthur Rouillé Media RelationsMedincell@newcap.eu / +33 (0)1 44 71 94 94\nLouis-Victor Delouvrier/Alban Dufumier Investor Relations FranceMedincell@newcap.eu / +33 (0)1 44 71 94 94","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}